替吉奥维持治疗对一线放化疗后局部晚期鼻咽癌患者的治疗效果分析  

Analysis of the therapeutic effect of maintenance treatment with Tegafur on patients with locally advanced nasopharyngeal carcinoma after first-line radiotherapy and chemotherapy

作　　者：王延磊 WANG Yan-lei(Department of Internal Medicine,People’s Hospital of Shanting District,Zaozhuang 277200,China)

机构地区：[1]枣庄市山亭区人民医院内四科,277200

出　　处：《中国实用医药》2022年第1期133-135,共3页China Practical Medicine

摘　　要：目的探讨替吉奥维持治疗一线放化疗后局部晚期鼻咽癌患者的临床疗效。方法58例晚期鼻咽癌患者作为研究对象,随机分为观察组与对照组,各29例。给予对照组患者支持治疗,给予观察组患者替吉奥维持治疗。对比两组患者治疗效果、1年生存率及不良反应发生情况。结果观察组患者接受替吉奥治疗2~12个周期,平均化疗周期为6个周期。观察组总缓解率(RR)为82.76%显著高于对照组的31.03%,差异有统计学意义(P<0.05)。两组患者均进行1年随访,观察组的1年生存率为79.31%明显高于对照组的48.28%,差异有统计学意义(P<0.05)。治疗后,观察组白细胞减少、贫血、胃肠道反应、口腔黏膜反应、肝功能损伤发生率分别为34.48%、17.24%、24.14%、10.34%、6.90%,均明显低于对照组的72.41%、41.38%、65.52%、44.83%、27.59%,差异有统计学意义(P<0.05)。结论将替吉奥应用于一线化疗后晚期鼻咽癌患者的维持治疗,可以延长患者的生存时间,其不良反应均可以耐受,而且具有安全、低毒、使用方便以及长期应用的临床特点,值得在临床晚期鼻咽癌患者的治疗中进行推广和使用。Objective To discuss the clinical efficacy of maintenance treatment with Tegafur on patients with locally advanced nasopharyngeal carcinoma after first-line radiotherapy and chemotherapy.Methods A total of 58 patients with advanced nasopharyngeal carcinoma as the research subjects were randomly divided into observation group and control group,with 29 cases in each group.Patients in the control group received supportive treatment,and patients in the observation group received maintenance treatment with Tegafur.The therapeutic effect,1-year survival rate and occurrence of adverse reactions were compared between the two groups.Results Patients in the observation group received Tegafur treatment for 2-12 cycles,with an average chemotherapy cycle of 6 cycles.The remission rate(RR)of the observation group was 82.76%,which was significantly higher than 31.03%of the control group,and the difference was statistically significant(P<0.05).Both groups were followed up for 1 year.The 1-year survival rate 79.31%of the observation group was significantly higher than 48.28%of the control group,and the difference was statistically significant(P<0.05).After treatment,the incidence of leukocytopenia,anemia,gastrointestinal reactions,oral mucosal reactions,and liver function damage in the observation group were 34.48%,17.24%,24.14%,10.34%,and 6.90%,which were significantly lower than 72.41%,41.38%,65.52%,44.83%,and 27.59%in the control group,and the difference was statistically significant(P<0.05).Conclusion The use of Tegafur in the maintenance treatment of advanced nasopharyngeal carcinoma patients after first-line radiotherapy and chemotherapy can prolong the survival time of patients with tolerable adverse effects,and has the clinical characteristics of safety,low toxicity,ease of use and long-term application,which is worthy of clinical promotion and application.

关 键 词：替吉奥维 一线放化疗 晚期鼻咽癌 治疗效果 

分 类 号：R739.63[医药卫生—肿瘤]